20,706 results on '"IMMUNOGENETICS"'
Search Results
2. Immunogenetics of lithium response and psychiatric phenotypes in patients with bipolar disorder.
- Author
-
Herrera-Rivero, Marisol, Gutiérrez-Fragoso, Karina, Kurtz, Joachim, and Baune, Bernhard
- Subjects
Humans ,Bipolar Disorder ,Lithium ,Retrospective Studies ,Immunogenetics ,Glycogen Synthase Kinase 3 beta ,Phenotype - Abstract
The link between bipolar disorder (BP) and immune dysfunction remains controversial. While epidemiological studies have long suggested an association, recent research has found only limited evidence of such a relationship. To clarify this, we performed an exploratory study of the contributions of immune-relevant genetic factors to the response to lithium (Li) treatment and the clinical presentation of BP. First, we assessed the association of a large collection of immune-related genes (4925) with Li response, defined by the Retrospective Assessment of the Lithium Response Phenotype Scale (Alda scale), and clinical characteristics in patients with BP from the International Consortium on Lithium Genetics (ConLi+Gen, N = 2374). Second, we calculated here previously published polygenic scores (PGSs) for immune-related traits and evaluated their associations with Li response and clinical features. Overall, we observed relatively weak associations (p
- Published
- 2024
3. The genomic landscape of the immune system in lung cancer: present insights and continuing investigations.
- Author
-
Roshan-Zamir, Mina, Khademolhosseini, Aida, Rajalingam, Kavi, Ghaderi, Abbas, and Rajalingam, Raja
- Subjects
genetic susceptibility ,genetic variation ,immunogenetics ,immunotherapy ,lung neoplasms - Abstract
Lung cancer is one of the most prevalent malignancies worldwide, contributing to over a million cancer-related deaths annually. Despite extensive research investigating the genetic factors associated with lung cancer susceptibility and prognosis, few studies have explored genetic predispositions regarding the immune system. This review discusses the most recent genomic findings related to the susceptibility to or protection against lung cancer, patient survival, and therapeutic responses. The results demonstrated the effect of immunogenetic variations in immune system-related genes associated with innate and adaptive immune responses, cytokine, and chemokine secretions, and signaling pathways. These genetic diversities may affect the crosstalk between tumor and immune cells within the tumor microenvironment, influencing cancer progression, invasion, and prognosis. Given the considerable variability in the individual immunegenomics profiles, future studies should prioritize large-scale analyses to identify potential genetic variations associated with lung cancer using highthroughput technologies across different populations. This approach will provide further information for predicting response to targeted therapy and promotes the development of new measures for individualized cancer treatment.
- Published
- 2024
4. High Resolution HLA-A, HLA-B, and HLA-C Allele Frequencies in Romanian Hematopoietic Stem Cell Donors.
- Author
-
Caragea, Andreea Mirela, Ursu, Radu-Ioan, Maruntelu, Ion, Tizu, Maria, Constantinescu, Alexandra-Elena, Tălăngescu, Adriana, and Constantinescu, Ileana
- Subjects
- *
HEMATOPOIETIC stem cells , *STEM cell donors , *HISTOCOMPATIBILITY class I antigens , *GENE frequency , *IMMUNOGENETICS , *ALLELES - Abstract
The HLA genes are associated with various autoimmune pathologies, with the control of the immune response also being significant in organs and cells transplantation. The aim of the study is to identify the HLA-A, HLA-B, and HLA-C alleles frequencies in the analyzed Romanian cohort. We performed HLA typing using next-generation sequencing (NGS) in a Romanian cohort to estimate class I HLA allele frequencies up to a six-digit resolution. A total of 420 voluntary donors from the National Registry of Voluntary Hematopoietic Stem Cell Donors (RNDVCSH) were included in the study for HLA genotyping. Peripheral blood samples were taken and brought to the Fundeni Clinical Institute during 2020–2021. HLA genotyping was performed using the Immucor Mia Fora NGS MFlex kit. A total of 109 different alleles were detected in 420 analyzed samples, out of which 31 were for HLA-A, 49 for HLA-B, and 29 for HLA-C. The most frequent HLA-A alleles were HLA-A*02:01:01 (26.11%), HLA-A*01:01:01 (12.5%), HLA-A*24:02:01 (11.67%), HLA-A*03:01:01 (9.72%), HLA-A*11:01:01, and HLA-A*32:01:01 (each with 8.6%). For the HLA-B locus, the most frequent allele was HLA-B*18:01:01 (11.25%), followed by HLA-B*51:01:01 (10.83%) and HLA-B*08:01:01 (7.78%). The most common HLA-C alleles were HLA-C*07:01:01 (17.36%), HLA-C*04:01:01 (13.47%), and HLA-C*12:03:01 (10.69%). Follow-up studies are ongoing for confirming the detected results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C.
- Author
-
Abdelaziz, Aya Ismail, Abdelsameea, Eman, Abdel-Samiee, Mohamed, Ghanem, Samar E., Wahdan, Sara A., Elsherbiny, Doaa A., Zakaria, Zeinab, and Azab, Samar S.
- Subjects
- *
EGYPTIANS , *IMMUNOGENETICS , *GENETIC polymorphisms , *PROMOTERS (Genetics) , *SINGLE nucleotide polymorphisms - Abstract
The prevalence of HCV infection in Egypt has decreased following the introduction of direct-acting antiviral therapy. However, treatment response is influenced by various factors, particularly host immunogenetics such as IL-28B and FOXP3 polymorphisms. The current study examined the impact of SNPs in the FOXP3 gene promoter region on HCV-infected Egyptian patients, along with SNPs in the IL28B gene.This study involved 99 HCV patients who achieved SVR12 after a 12 week DAA treatment while 63 HCV patients experienced treatment failure. IL28B rs12979860 SNP was identified using real-time PCR, while IL28B rs8099917, FOXP3 rs3761548, and rs2232365 SNPs were analyzed using RFLP-PCR. Serum levels of IL28B and FOXP3 were quantified using ELISA technique in representative samples from both groups. The IL28B rs12979860 T > C (P = 0.013) and FOXP3 rs2232365 A > G polymorphisms (P = 0.008) were found to significantly increase the risk of non-response. Responders had higher IL28B serum levels (P = 0.046) and lower FOXP3 levels (P < 0.001) compared to non-responders. Regression analysis showed an association between IL28B rs12979860 and FOXP3 rs2232365 with treatment response, independent of age and gender. A predictive model was developed with 76.2% sensitivity and 91.9% specificity for estimating DAAs response in HCV patients.Our findings confirmed the IL28B rs12979860 T > C and FOXP3 rs2232365 A > G polymorphisms significantly affect DAA treatment response in HCV Egyptian patients. Lower levels of IL-28B along with higher levels of FOXP3 are linked to poor response. Our results may lead to new insights into DAA responsiveness contributing to personalized medicine and improving therapeutic decision-making for HCV patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Killer‐cell immunoglobulin‐like receptor polymorphism is associated with COVID‐19 outcome: Results of a pilot observational study.
- Author
-
Niño‐Ramírez, J. E., Alcoceba, M., Gutiérrez‐Zufiaurre, M. N., Marcos, M., Gil‐Etayo, F. J., Bartol‐Sánchez, M. R., Eiros, R., Chillón, M. C., García‐Álvarez, M., Terradillos‐Sánchez, P., Presa, D., Muñoz, J. L., López‐Bernús, A., López‐Sánchez, E., González‐Calle, D., Sánchez, P. L., Compán‐Fernández, O., González, M., García‐Sanz, R., and Boix, F.
- Subjects
- *
LOGISTIC regression analysis , *GENETIC polymorphisms , *POLYMORPHISM (Zoology) , *TREATMENT effectiveness , *IMMUNOGENETICS - Abstract
The pathogenesis of COVID‐19 warrants unravelling. Genetic polymorphism analysis may help answer the variability in disease outcome. To determine the role of KIR and HLA polymorphisms in susceptibility, progression, and severity of SARS‐CoV‐2 infection, 458 patients and 667 controls enrolled in this retrospective observational study from April to December 2020. Mild/moderate and severe/death study groups were established. HLA‐A, ‐B, ‐C, and KIR genotyping were performed using the Lifecodes® HLA‐SSO and KIR‐SSO kits on the Luminex® 200™ xMAP fluoroanalyser. A probability score using multivariate binary logistic regression analysis was calculated to estimate the likelihood of severe COVID‐19. ROC analysis was used to calculate the best cut‐off point for predicting a worse clinical outcome with high sensitivity and specificity. A p ≤ 0.05 was considered statistically significant. KIR AA genotype protected positively against severity/death from COVID‐19. Furthermore, KIR3DL1, KIR2DL3 and KIR2DS4 genes protected patients from severe forms of COVID‐19. KIR Bx genotype, as well as KIR2DL2, KIR2DS2, KIR2DS3 and KIR3DS1 were identified as biomarkers of severe COVID‐19. Our logistic regression model, which included clinical and KIR/HLA variables, categorised our cohort of patients as high/low risk for severe COVID‐19 disease with high sensitivity and specificity (Se = 94.29%, 95% CI [80.84–99.30]; Sp = 84.55%, 95% CI [79.26–88.94]; OR = 47.58, 95%CI [11.73–193.12], p < 0.0001). These results illustrate an association between KIR/HLA ligand polymorphism and different COVID‐19 outcomes and remarks the possibility of use them as a surrogate biomarkers to detect severe patients in possible future infectious outbreaks. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Plethora of New Marsupial Genomes Informs Our Knowledge of Marsupial MHC Class II.
- Author
-
Silver, Luke W, Hogg, Carolyn J, and Belov, Katherine
- Subjects
- *
LIFE history theory , *GENE families , *IMMUNOGENETICS , *CHLAMYDIA infections , *COMPARATIVE genomics - Abstract
The major histocompatibility complex (MHC) plays a vital role in the vertebrate immune system due to its role in infection, disease and autoimmunity, or recognition of "self". The marsupial MHC class II genes show divergence from eutherian MHC class II genes and are a unique taxon of therian mammals that give birth to altricial and immunologically naive young providing an opportune study system for investigating evolution of the immune system. Additionally, the MHC in marsupials has been implicated in disease associations, including susceptibility to Chlamydia pecorum infection in koalas. Due to the complexity of the gene family, automated annotation is not possible so here we manually annotate 384 class II MHC genes in 29 marsupial species. We find losses of key components of the marsupial MHC repertoire in the Dasyuromorphia order and the Pseudochiridae family. We perform PGLS analysis to show the gene losses we find are true gene losses and not artifacts of unresolved genome assembly. We investigate the associations between the number of loci and life history traits, including lifespan and reproductive output in lineages of marsupials and hypothesize that gene loss may be linked to the energetic cost and tradeoffs associated with pregnancy and reproduction. We found support for litter size being a significant predictor of the number of DBA and DBB loci, indicating a tradeoff between the energetic requirements of immunity and reproduction. Additionally, we highlight the increased susceptibility of Dasyuridae species to neoplasia and a potential link to MHC gene loss. Finally, these annotations provide a valuable resource to the immunogenetics research community to move forward and further investigate diversity in MHC genes in marsupials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Analysis of HLA Alleles in Different Cohorts of Patients Infected by L. infantum from Southern Spain.
- Author
-
Gutiérrez-Bautista, Juan Francisco, Sampedro, Antonio, Ballesta-Alcaraz, Lucia, Aguilera-Franco, María, Olivares-Durán, María José, Cobo, Fernando, Reguera, Juan Antonio, Rodríguez-Granger, Javier, Torres-Llamas, Andrés, Martín-Sánchez, Joaquina, Aznar-Peralta, Inés, Vilchez, Jose Ramon, López-Nevot, Miguel Ángel, and Sampedro-Martínez, Antonio
- Subjects
- *
HLA histocompatibility antigens , *HAPLOTYPES , *LEISHMANIA infantum , *COMMUNICABLE diseases , *LEISHMANIASIS - Abstract
Leishmaniasis is an infectious disease caused by protozoa of the genus Leishmania, which is endemic in certain areas of Europe, such as southern Spain. The disease manifests in various clinical phenotypes, including visceral, cutaneous, mucosal, or asymptomatic leishmaniasis. This diversity in clinical outcomes may be influenced by the host immune response, with human leukocyte antigen (HLA) molecules playing a crucial role in determining susceptibility and progression of the infection. This study explores the association between specific HLA variants and Leishmania infantum infection. We recruited four cohorts: a control group, asymptomatic individuals, patients with symptomatic disease, and cohabitants of infected individuals. HLA typing was performed for all participants, followed by an association analysis with infection status and disease progression. Our findings indicate that the HLA-B*38 and HLA-C*03 alleles are associated with protection against L. infantum infection. These results contribute to a better understanding of the disease's progression, offer potential for new therapeutic approaches such as vaccines, and expand the existing knowledge in the literature. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Forming a new perspective: Post‐structural approaches to determination of donor compatibility and post‐transplant assessment of allograft health.
- Author
-
Nadat, Fatima and Clark, Brendan
- Subjects
- *
IMMUNOGENETICS , *ALLOCATION of organs, tissues, etc. , *HOMOGRAFTS , *IMMUNE system , *HISTOCOMPATIBILITY , *IMMUNITY - Abstract
The purpose of this review is to encourage a new perspective on the question of donor–recipient compatibility and post‐transplant assessment of graft health based on functional measures. The premise is that we should be better sighted on what (and how) the immune system responds toward rather than what is merely there. Continuance of the pursuit of further and better definition of antigens and antibodies is not however discouraged but seen as necessary to improved understanding of the structural correlates of functional immunity. There currently exists, in the opinion of the authors, an opportunity for histocompatibility and immunogenetics laboratories to develop and widen their scope of involvement into these new areas of laboratory activity in support and to the benefit of the transplant programmes they serve. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. IMGT/mAb-KG: the knowledge graph for therapeutic monoclonal antibodies.
- Author
-
Sanou, Gaoussou, Manso, Taciana, Todorov, Konstantin, Giudicelli, Véronique, Duroux, Patrice, and Kossida, Sofia
- Subjects
KNOWLEDGE graphs ,MONOCLONAL antibodies ,SEMANTIC Web ,GRAFT rejection ,DATABASES - Abstract
Introduction: Therapeutic monoclonal antibodies (mAbs) have demonstrated promising outcomes in diverse clinical indications, including but not limited to graft rejection, cancer, and autoimmune diseases lately.Recognizing the crucial need for the scientific community to quickly and easily access dependable information on monoclonal antibodies (mAbs), IMGT®, the international ImMunoGeneTics information system®, provides a unique and invaluable resource: IMGT/mAb-DB, a comprehensive database of therapeutic mAbs, accessible via a user-friendly web interface. However, this approach restricts more sophisticated queries and segregates information from other databases. Methods: To connect IMGT/mAb-DB with the rest of the IMGT databases, we created IMGT/mAb-KG, a knowledge graph for therapeutic monoclonal antibodies connected to IMGT structures and genomics databases. IMGT/ mAb-KG is developed using the most effective methodologies and standards of semantic web and acquires data from IMGT/mAb-DB. Concerning interoperability, IMGT/mAb-KG reuses terms from biomedical resources and is connected to related resources. Results and discussion: In February 2024, IMGT/mAb-KG, encompassing a total of 139,629 triplets, provides access to 1,489 mAbs, approximately 500 targets, and over 500 clinical indications. It offers detailed insights into the mechanisms of action of mAbs, their construction, and their various products and associated studies. Linked to other resources such as Thera-SAbDab (Therapeutic Structural Antibody Database), PharmGKB (a comprehensive resource curating knowledge on the impact of genetic variation on drug response), PubMed, and HGNC (HUGO Gene Nomenclature Committee), IMGT/mAb-KG is an essential resource for mAb development. A user-friendly web interface facilitates the exploration and analyse of the content of IMGT/mAb-KG. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. 57. Jahrestagung der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie e.V. (DGTI) gemeinsam mit der 31. Jahrestagung der Deutschen Gesellschaft für Immungenetik (DGI) – Abstracts.
- Subjects
- *
BLOOD disease treatment , *IMMUNOGENETICS , *IMMUNOTHERAPY , *CONFERENCES & conventions , *BLOOD transfusion - Published
- 2024
- Full Text
- View/download PDF
12. Systematic characterization of immunoglobulin loci and deep sequencing of the expressed repertoire in the Atlantic cod (Gadus morhua).
- Author
-
Györkei, Ádám, Johansen, Finn-Eirik, and Qiao, Shuo-Wang
- Subjects
- *
ATLANTIC cod , *ANTIBODY diversity , *T cells , *IMMUNOGLOBULIN genes , *IMMUNOGLOBULIN analysis , *GENE families , *T cell receptors - Abstract
Background: The Atlantic cod is a prolific species in the Atlantic, despite its inconsistent specific antibody response. It presents a peculiar case within vertebrate immunology due to its distinct immune system, characterized by the absence of MHCII antigen presentation pathway, required for T cell-dependent antibody responses. Thorough characterisation of immunoglobulin loci and analysis of the antibody repertoire is necessary to further our understanding of the Atlantic cod's immune response on a molecular level. Results: A comprehensive search of the cod genome (gadmor3.0) identified the complete set of IgH genes organized into three sequential translocons on chromosome 2, while IgL genes were located on chromosomes 2 and 5. The Atlantic cod displayed a moderate germline V gene diversity, comprising four V gene families for both IgH and IgL, each with distinct chromosomal locations and organizational structures. 5'RACE sequencing revealed a diverse range of heavy chain CDR3 sequences and relatively limited CDR3 diversity in light chains. The analysis highlighted a differential impact of V-gene germline CDR3 length on receptor CDR3 length between heavy and light chains, underlining different recombination processes. Conclusions: This study reveals that the Atlantic cod, despite its inconsistent antibody response, maintains a level of immunoglobulin diversity comparable to other fish species. The findings suggest that the extensive recent duplications of kappa light chain genes do not result in increased repertoire diversity. This research provides a comprehensive view of the Atlantic cod's immunoglobulin gene organization and repertoire, necessary for future studies of antibody responses at the molecular level. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Patterns of Evolution of TRIM Genes Highlight the Evolutionary Plasticity of Antiviral Effectors in Mammals.
- Author
-
Fernandes, Alexandre, OhAinle, Molly, and Esteves, Pedro
- Subjects
TRIM ,TRIM5 ,immunogenetics ,positive selection ,restriction factors ,retrovirus evolution ,Animals ,Antiviral Restriction Factors ,Tripartite Motif Proteins ,Proteins ,Ubiquitin-Protein Ligases ,Mammals ,Eutheria - Abstract
The innate immune system of mammals is formed by a complex web of interacting proteins, which together constitute the first barrier of entry for infectious pathogens. Genes from the E3-ubiquitin ligase tripartite motif (TRIM) family have been shown to play an important role in the innate immune system by restricting the activity of different retrovirus species. For example, TRIM5 and TRIM22 have both been associated with HIV restriction and are regarded as crucial parts of the antiretroviral machinery of mammals. Our analyses of positive selection corroborate the great significance of these genes for some groups of mammals. However, we also show that many species lack TRIM5 and TRIM22 altogether. By analyzing a large number of mammalian genomes, here we provide the first comprehensive view of the evolution of these genes in eutherians, showcasing that the pattern of accumulation of TRIM genes has been dissimilar across mammalian orders. Our data suggest that these differences are caused by the evolutionary plasticity of the immune system of eutherians, which have adapted to use different strategies to combat retrovirus infections. Altogether, our results provide insights into the dissimilar evolution of a representative family of restriction factors, highlighting an example of adaptive and idiosyncratic evolution in the innate immune system.
- Published
- 2023
14. Systematic characterization of immunoglobulin loci and deep sequencing of the expressed repertoire in the Atlantic cod (Gadus morhua)
- Author
-
Ádám Györkei, Finn-Eirik Johansen, and Shuo-Wang Qiao
- Subjects
Atlantic cod ,Immunogenetics ,Ig ,Repertoire ,Diversity ,Gadmor3.0 ,Biotechnology ,TP248.13-248.65 ,Genetics ,QH426-470 - Abstract
Abstract Background The Atlantic cod is a prolific species in the Atlantic, despite its inconsistent specific antibody response. It presents a peculiar case within vertebrate immunology due to its distinct immune system, characterized by the absence of MHCII antigen presentation pathway, required for T cell-dependent antibody responses. Thorough characterisation of immunoglobulin loci and analysis of the antibody repertoire is necessary to further our understanding of the Atlantic cod’s immune response on a molecular level. Results A comprehensive search of the cod genome (gadmor3.0) identified the complete set of IgH genes organized into three sequential translocons on chromosome 2, while IgL genes were located on chromosomes 2 and 5. The Atlantic cod displayed a moderate germline V gene diversity, comprising four V gene families for both IgH and IgL, each with distinct chromosomal locations and organizational structures. 5’RACE sequencing revealed a diverse range of heavy chain CDR3 sequences and relatively limited CDR3 diversity in light chains. The analysis highlighted a differential impact of V-gene germline CDR3 length on receptor CDR3 length between heavy and light chains, underlining different recombination processes. Conclusions This study reveals that the Atlantic cod, despite its inconsistent antibody response, maintains a level of immunoglobulin diversity comparable to other fish species. The findings suggest that the extensive recent duplications of kappa light chain genes do not result in increased repertoire diversity. This research provides a comprehensive view of the Atlantic cod's immunoglobulin gene organization and repertoire, necessary for future studies of antibody responses at the molecular level.
- Published
- 2024
- Full Text
- View/download PDF
15. Systems Biology: A New Era for Vaccine Development; from Deductive Toward Inductive
- Author
-
Debnath, Usnik, Ghosh, Sahana, Joshi, Sanket, editor, Ray, Rina Rani, editor, Nag, Moupriya, editor, and Lahiri, Dibyajit, editor
- Published
- 2024
- Full Text
- View/download PDF
16. Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation.
- Author
-
Xu, Zhi Ming, Gnouamozi, Gnimah Eva, Rüeger, Sina, Shea, Patrick R., Buti, Maria, Chan, Henry LY., Marcellin, Patrick, Lawless, Dylan, Naret, Olivier, Zeller, Matthias, Schneuing, Arne, Scheck, Andreas, Junier, Thomas, Moradpour, Darius, Podlaha, Ondrej, Suri, Vithika, Gaggar, Anuj, Subramanian, Mani, Correia, Bruno, and Gfeller, David
- Subjects
- *
HEPATITIS B virus , *GENOMICS , *VIRAL mutation , *CHRONIC hepatitis B , *GENETIC variation , *VIRAL variation - Abstract
Evolutionary changes in the hepatitis B virus (HBV) genome could reflect its adaptation to host-induced selective pressure. Leveraging paired human exome and ultra-deep HBV genome-sequencing data from 567 affected individuals with chronic hepatitis B, we comprehensively searched for the signatures of this evolutionary process by conducting "genome-to-genome" association tests between all human genetic variants and viral mutations. We identified significant associations between an East Asian-specific missense variant in the gene encoding the HBV entry receptor NTCP (rs2296651, NTCP S267F) and mutations within the receptor-binding region of HBV preS1. Through in silico modeling and in vitro preS1-NTCP binding assays, we observed that the associated HBV mutations are in proximity to the NTCP variant when bound and together partially increase binding affinity to NTCP S267F. Furthermore, we identified significant associations between HLA-A variation and viral mutations in HLA-A-restricted T cell epitopes. We used in silico binding prediction tools to evaluate the impact of the associated HBV mutations on HLA presentation and observed that mutations that result in weaker binding affinities to their cognate HLA alleles were enriched. Overall, our results suggest the emergence of HBV escape mutations that might alter the interaction between HBV PreS1 and its cellular receptor NTCP during viral entry into hepatocytes and confirm the role of HLA class I restriction in inducing HBV epitope variations. [Display omitted] Host-induced selective pressure can shape viral evolution during chronic infections. By analyzing paired human and hepatitis B virus (HBV) genomic data, we pinpoint viral mutations associated with human NTCP and HLA-A variation, shedding light on HBV-evasion strategies that influence viral entry and HLA presentation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Immunogenicity of Monovalent mRNA-1273 and BNT162b2 Vaccines in Children <5 Years of Age.
- Author
-
Dalapati, Trisha, Williams, Caitlin A., Giorgi, Elena E., Hurst, Jillian H., Herbek, Savannah, Jui-Lin Chen, Kosman, Christina, Rotta, Alexandre T., Turner, Nicholas A., Pulido, Natalie, Aquino, Jhoanna N., Pfeiffer, Trevor S., Rodriguez, Javier, Fouda, Genevieve G., Permar, Sallie R., and Kelly, Matthew S.
- Subjects
- *
SARS disease , *IMMUNOGENETICS , *RESEARCH funding , *VACCINE effectiveness , *IMMUNOGLOBULINS , *POLYMERASE chain reaction , *COVID-19 vaccines , *DESCRIPTIVE statistics , *MESSENGER RNA , *LONGITUDINAL method , *VACCINE immunogenicity , *COMPARATIVE studies , *GENETIC mutation , *SARS-CoV-2 , *CHILDREN - Abstract
BACKGROUND AND OBJECTIVES: The messenger RNA (mRNA)-based coronavirus disease 2019 vaccines approved for use in children <5 years of age have different antigen doses and administration schedules that could affect vaccine immunogenicity and effectiveness. We sought to compare the strength and breadth of serum binding and neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicited by monovalent mRNA-based coronavirus disease 2019 vaccines in young children. METHODS: We conducted a prospective cohort study of children 6 months to 4 years of age who completed primary series vaccination with monovalent mRNA-1273 or BNT162b2 vaccines. Serum was collected 1 month after primary vaccine series completion for the measurement of SARS-CoV-2-specific humoral immune responses, including antibody binding responses to Spike proteins from an ancestral strain (D614G) and major variants of SARS-CoV-2 and antibody neutralizing activity against D614G and Omicron subvariants (BA.1, BA.4/5). RESULTS: Of 75 participants, 40 (53%) received mRNA-1273 and 35 (47%) received BNT162b2. Children receiving either primary vaccine series developed robust and broad SARS-CoV-2-specific binding and neutralizing antibodies, including to Omicron subvariants. Children with a previous history of SARS-CoV-2 infection developed significantly higher antibody binding responses and neutralization titers to Omicron subvariants, which is consistent with the occurrence of identified infections during the circulation of Omicron subvariants in the region. CONCLUSIONS: Monovalent mRNA-1273 and BNT162b2 elicited similar antibody responses 1 month after vaccination in young children. In addition, previous infection significantly enhanced the strength of antibody responses to Omicron subvariants. The authors of future studies should evaluate incorporation of these vaccines into the standard childhood immunization schedule. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. The 18th International HLA & Immunogenetics workshop project report: Creating fully representative MHC reference haplotypes.
- Author
-
Pollock, Nicholas R., Farias, Ticiana D. J., Kichula, Katherine M., Sauter, Jürgen, Scholz, Stephan, Nii‐Trebi, Nicholas I., Khor, Seik‐Soon, Tokunaga, Katsushi, Voorter, Christina E., Groeneweg, Mathijs, Augusto, Danillo G., Arrieta‐Bolaños, Esteban, Mayor, Neema P., Edinur, Hisham Atan, ElGhazali, Gehad, Issler, Hellen C., Petzl‐Erler, Maria Luiza, Oksenberg, Jorge R., Marin, Wesley M., and Hollenbach, Jill A.
- Subjects
- *
MAJOR histocompatibility complex , *IMMUNOGENETICS , *HAPLOTYPES , *LIFE sciences , *GENE libraries , *NUCLEOTIDE sequencing - Abstract
This document provides an overview of a project aimed at creating a database of Major Histocompatibility Complex (MHC) reference sequences to enhance research on immune response genetics. The current human genome reference is limited in diversity as it only includes alleles of European origin. To address this, the International Histocompatibility Working Group (IHWG) is collecting and sequencing samples representing HLA haplotypes from non-European populations. The project involves high-throughput targeted sequencing and bioinformatics pipelines to analyze DNA samples from various countries, with a focus on increasing representation from populations outside of Europe. Efforts are ongoing to collect more samples from underrepresented regions such as Africa, South Asia, and Oceania. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
19. Homozygous HLA‐DQB1*06:02 combined with T‐cell receptor alpha polymorphism results in narcolepsy onset – A familial case report.
- Author
-
Jervis, Steven, Payton, Antony, Verma, Arpana, Thomasson, Rachel, and Poulton, Kay
- Subjects
- *
T-cell receptor genes , *NARCOLEPSY , *GENETIC disorders , *GENETIC markers , *HEREDITY , *T cells - Abstract
Narcolepsy is a life‐long neurological disorder with well‐established genetic risk factors. Human leukocyte antigen‐DQB1*06:02 remains the strongest genetic predeterminant; however, polymorphisms in genes encoding the T‐cell receptor alpha chain are also strongly linked. This case report shows the inheritance pathway of these genetic markers contributing to narcolepsy onset in a 17‐year‐old female. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Analysis of immunogenetics interlaboratory comparisons' success rates. External quality assurance system of the Spanish Society for Immunology GECLID-SEI.
- Author
-
Martín, M. Carmen
- Subjects
QUALITY assurance ,HLA histocompatibility antigens ,HISTOCOMPATIBILITY testing ,IMMUNOGENETICS ,IMMUNOLOGY ,EUROPEAN integration - Abstract
Background: For many years, transplantation outcomes were uncertain and not hopeful, until histocompatibility testing spread. Common criteria for histocompatibility assays and communications' improvement allowed an efficient organ sharing system. The possibility of organ exchanges is closely linked to the importance of interlaboratory comparisons for histocompatibility and immunogenetics methods. The external proficiency testing (EPT) systems are the most powerful quality assurance tools. They help achieve harmonization of analyses, set a standard of performance, and a common interpretation. Methods: The external quality assurance program for diagnostic immunology laboratories (Garantía Externa de Calidad para Laboratorios de Inmunología Diagnóstica, GECLID) program nowadays runs 13 external quality assurance (EQA) histocompatibility and immunogenetics schemes, with the first of them from 2011 to date: serological and molecular: low- and high-resolution human leukocyte antigen (HLA), human platelet antigen (HPA), and killer inhibitory receptor (KIR) typing(HLA-B*27, HLA-B*57:01, and coeliac disease-related HLA), cell-dependent cytotoxicity (CDC) and flow cytometry (FC) crossmatches, anti-HLA and anti-HPA antibodies, and chimerism. Results: A total of 85 laboratories participated in this subprogram in the last 12years reporting over 1.69 M results: 1.46 M for anti-HLA and anti-HPA antibodies, 203.810 molecular typing data (HLA, HPA, and KIR genes), 2.372 for chimerism analyses, and 39.352 for crossmatches. Based on the European Federation for Immunogenetics (EFI) standards for EPT providers, the mean success rates ranged from 99.2% for molecular typing schemes and antibodies and 94.8% for chimerism, was 96.7% regarding crossmatches, and was 98.9% in serological typing. In 2022, 61.3% of the participating laboratories successfully passed every HLA EQA scheme, although 87.9% annual reports were satisfactory. Most penalties were due to nomenclature errors or misreporting of the risk associated to HLA and disease. Conclusion: This EQA confirms the reliability of HLA and immunogenetics assays in routine care. There is little heterogeneity of results of different assays used by participating laboratories, even when in-house assays are used. Reliability of test results is reasonably granted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Advancements in HLA Typing Techniques and Their Impact on Transplantation Medicine.
- Author
-
Geo, Jeethu Anu, Ameen, Reem, Al Shemmari, Salem, and Thomas, Jibu
- Subjects
- *
STEM cell transplantation , *HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *GRAFT rejection , *NUCLEOTIDE sequencing , *DNA fingerprinting , *COST control - Abstract
HLA typing serves as a standard practice in hematopoietic stem cell transplantation to ensure compatibility between donors and recipients, preventing the occurrence of allograft rejection and graft-versus-host disease. Conventional laboratory methods that have been widely employed in the past few years, including sequence-specific primer PCR and sequencing-based typing (SBT), currently face the risk of becoming obsolete. This risk stems not only from the extensive diversity within HLA genes but also from the rapid advancement of next-generation sequencing and third-generation sequencing technologies. Third-generation sequencing systems like single-molecule real-time (SMRT) sequencing and Oxford Nanopore (ONT) sequencing have the capability to analyze long-read sequences that span entire intronic-exonic regions of HLA genes, effectively addressing challenges related to HLA ambiguity and the phasing of multiple short-read fragments. The growing dominance of these advanced sequencers in HLA typing is expected to solidify further through ongoing refinements, cost reduction, and error rate minimization. This review focuses on hematopoietic stem cell transplantation (HSCT) and explores prospective advancements and application of HLA DNA typing techniques. It explores how the adoption of third-generation sequencing technologies can revolutionize the field by offering improved accuracy, reduced ambiguity, and enhanced assessment of compatibility in HSCT. Embracing these cutting-edge technologies is essential to advancing the success rates and outcomes of hematopoietic stem cell transplantation. This review underscores the importance of staying at the forefront of HLA typing techniques to ensure the best possible outcomes for patients undergoing HSCT. Highlights of the Study: This review delves into the progression of HLA typing techniques, from serology to high-resolution sequencing methods, and emphasizes the pivotal role of HLA compatibility in stem cell transplantation. We discuss resolution levels for precise HLA typing and highlight the transformative potential of PacBio and nanopore sequencing. Precise HLA typing revolutionizes transplantation, improving donor-recipient matching and reducing ambiguities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study
- Author
-
Danto, Spencer I., Tsamandouras, Nikolaos, Reddy, Padmalatha, Gilbert, Steven, Mancuso, Jessica, Page, Karen, Peeva, Elena, Vincent, Michael S., and Beebe, Jean S.
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *ATOPIC dermatitis , *PHARMACEUTICAL arithmetic , *IMMUNOGENETICS , *PATIENT safety , *HEALTH status indicators , *DRUG side effects , *BODY mass index , *SINUSITIS , *RANDOMIZED controlled trials , *DESCRIPTIVE statistics , *NASAL polyps , *MONOCLONAL antibodies , *CHRONIC diseases , *INTRAVENOUS therapy , *SERUM , *LONGITUDINAL method , *DRUG tolerance , *INTERLEUKINS , *REGRESSION analysis , *AMINOTRANSFERASES - Abstract
PF‐06817024 is a high affinity, humanized antibody that binds interleukin‐33, a proinflammatory type 2 cytokine, and thereby has the potential to inhibit downstream type 2 inflammation. This Phase 1, randomized, placebo‐controlled study was conducted in 3 parts to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics of escalating single and limited repeat PF‐06817024 doses in healthy participants (Part 1), a single dose of PF‐06817024 in participants with chronic rhinosinusitis with nasal polyps (Part 2), and repeat doses of PF‐06817024 in participants with moderate to severe atopic dermatitis (atoptic dermatitis; Part 3). PF‐06817024 was generally well tolerated in all participant populations. Most participants experienced a treatment‐emergent adverse event (healthy participants, 78.4% and 100%; participants with chronic rhinosinusitis with nasal polyps, 90.9% and 88.9%; and participants with atoptic dermatitis, 60.0% and 62.5% in the PF‐06817024 and placebo groups, respectively). No substantial deviations from dose proportionality were observed for single intravenous doses of 10‐1000 mg, indicating linear PK in healthy participants. Mean terminal half‐life ranged from 83 to 94 days after single intravenous administration in healthy participants and was similar to that observed after administration in the studied patient populations. Incidences of antidrug antibodies in the studied populations were 10.8%, 9.1%, and 5.0% for healthy participants, participants with chronic rhinosinusitis with nasal polyps, and participants with atoptic dermatitis, respectively. In addition, dose‐dependent increases were observed in total serum interleukin‐33 levels of treated participants, indicating target engagement. Overall, the PK and safety profile of PF‐06817024 supports further investigation of the drug as a potential treatment for allergic diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. A Short History of B-Cell HLA Epitopes.
- Author
-
Doxiadis, Ilias, Loeffler-Wirth, Henry, Lachmann, Nils, and Lehmann, Claudia
- Subjects
- *
PROTEIN analysis , *IMMUNOGLOBULIN analysis , *IMMUNOGENETICS , *TRANSPLANTATION of organs, tissues, etc. , *T cells , *REPORTING of diseases , *PEPTIDES , *ANTIGEN-antibody reactions , *ADULT education workshops , *B cells , *HLA-B27 antigen , *ALLELES , *SEQUENCE analysis , *IMMUNITY - Abstract
Background: HLA epitopes are currently in the focus of transplantation immunogenetics. The main reason is the complexity of the HLA system with >38,000 alleles, the number of which increases steadily. These alleles are determined by the current state-of-the art typing methods like second- and third-generation sequencing. Screening for HLA antibodies is hampered by the lack of specific target beads with all possible alleles described. Summary: A way to circumvent the problem is to define HLA epitopes. The number of antibody-confirmed epitopes, on the other hand, was found to be 72 for HLA class I and 74 for HLA class II. Here, we elaborate on the current knowledge on these HLA epitopes. Absolute definitions of these structures are not yet available. Key Messages: Making use of eplets is a comparable way allowing statistical analyses. However, one should keep in mind that the results obtained are approximative or perhaps better associative. Continuous collaboration is needed for the full understanding of the HLA epitopes. The reactivity toward epitopes remains patient-specific. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Immunogenetics of Systemic Sclerosis.
- Author
-
Gumkowska-Sroka, Olga, Kotyla, Kacper, and Kotyla, Przemysław
- Subjects
- *
SYSTEMIC scleroderma , *MOLECULAR biology , *IMMUNOGENETICS , *GENETIC markers , *DISEASE susceptibility , *GENETIC variation , *IMMUNE response - Abstract
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disorder characterized by massive fibrosis, vascular damage, and immune imbalance. Advances in rheumatology and immunology over the past two decades have led to a redefinition of systemic sclerosis, shifting from its initial perception as primarily a "hyperfibrotic" state towards a recognition of systemic sclerosis as an immune-mediated disease. Consequently, the search for genetic markers has transitioned from focusing on fibrotic mechanisms to exploring immune regulatory pathways. Immunogenetics, an emerging field at the intersection of immunology, molecular biology, and genetics has provided valuable insights into inherited factors that influence immunity. Data from genetic studies conducted thus far indicate that alterations in genetic messages can significantly impact disease risk and progression. While certain genetic variations may confer protective effects, others may exacerbate disease susceptibility. This paper presents a comprehensive review of the most relevant genetic changes that influence both the risk and course of systemic sclerosis. Special emphasis is placed on factors regulating the immune response, recognizing their pivotal role in the pathogenesis of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. PyPop: a mature open-source software pipeline for population genomics.
- Author
-
Lancaster, Alexander K., Single, Richard M., Mack, Steven J., Sochat, Vanessa, Marian, Michael P., and Webster, Gordon D.
- Subjects
GENOMICS ,POPULATION genetics ,LINKAGE disequilibrium ,IMMUNOGENETICS ,SCIENTIFIC community - Abstract
Python for Population Genomics (PyPop) is a software package that processes genotype and allele data and performs large-scale population genetic analyses on highly polymorphic multi-locus genotype data. In particular, PyPop tests data conformity to Hardy-Weinberg equilibrium expectations, performs Ewens-Watterson tests for selection, estimates haplotype frequencies, measures linkage disequilibrium, and tests significance. Standardized means of performing these tests is key for contemporary studies of evolutionary biology and population genetics, and these tests are central to genetic studies of disease association as well. Here, we present PyPop 1.0.0, a new major release of the package, which implements new features using the more robust infrastructure of GitHub, and is distributed via the industry-standard Python Package Index. New features include implementation of the asymmetric linkage disequilibrium measures and, of particular interest to the immunogenetics research communities, support for modern nomenclature, including colon-delimited allele names, and improvements to meta-analysis features for aggregating outputs for multiple populations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti‐Transcriptional Intermediary Factor 1γ Juvenile‐Onset Dermatomyositis.
- Author
-
Sherman, Matthew A., Yang, Qingyuan, Gutierrez‐Alamillo, Laura, Pak, Katherine, Flegel, Willy A., Mammen, Andrew L., Rider, Lisa G., Casciola‐Rosen, Livia A., Arabshahi, Bita, Ballinger, Susan, April Bingham, C., Bohnsack, John F., Carrasco, Ruy, Anne Eberhardt, B., Edelheit, Barbara S., Farhadi, Payam Noroozi, Finkel, Terri H., Fuhlbrigge, Robert C., Goldmuntz, Ellen A., and Gottlieb, Beth S.
- Subjects
- *
TUMOR risk factors , *DERMATOMYOSITIS , *IMMUNOGENETICS , *RISK assessment , *CROSS-sectional method , *AUTOANTIBODIES , *LOGISTIC regression analysis , *TRANSCRIPTION factors , *DESCRIPTIVE statistics , *CHI-squared test , *MANN Whitney U Test , *AGE factors in disease , *LONGITUDINAL method , *ODDS ratio , *CONFIDENCE intervals , *FACTOR analysis , *HLA-B27 antigen , *BIOMARKERS , *GENOTYPES , *ADULTS - Abstract
Objective: Novel autoantibody specificities including anti‐CCAR1 were recently discovered in adult patients with anti‐transcriptional intermediary factor (TIF1)–positive dermatomyositis (DM) and were associated with attenuated cancer emergence. The aims of the present study were to examine whether these autoantibodies occur in patients with juvenile‐onset DM (JDM) and to determine their associated features. Methods: Sera from 150 patients with anti‐TIF1γ autoantibody‐positive JDM in a cross‐sectional cohort and 90 juvenile healthy controls were assayed for anti‐CCAR1, anti‐C1Z1, anti‐IMMT, anti‐TBL1XR1, and anti‐Sp4 autoantibodies. Demographics, myositis autoantibodies, clinical features, medications, outcomes, and HLA‐DRB1 and HLA‐DQA1 alleles were compared between those with and without these autoantibodies. Results: Any one of the anti‐TIF1γ‐associated autoantibodies was present in 44 patients (29%) overall, including 25 (17%) with anti‐Sp4, 22 (15%) with anti‐TBL1XR1, 14 (9%) with anti‐CCAR1, 2 (1%) with anti‐C1Z1, and 2 (1%) with anti‐IMMT autoantibodies. These anti‐TIF1γ‐associated autoantibodies frequently co‐occurred. Patients with any of the anti‐TIF1γ‐associated autoantibodies had less frequent falling (34% [15] vs. 53% [56], P = 0.032) and lower peak muscle enzymes. None of the patients had cancer. Among White patients, HLA‐DRB1*03 was protective against an anti‐TIF1γ‐associated autoantibody (odds ratio 0.20, 95% confidence interval 0.07–0.52). Conclusion: Autoantibodies associated with anti‐TIF1γ were found in isolation and in combination among a subset of patients with JDM. Patients with these autoantibodies had less severe muscle disease and were not enriched for HLA‐DRB1*03. Additional autoantibodies among patients with positive anti‐TIF1γ with JDM likely contribute to the heterogeneity of the anti‐TIF1γ serologic subgroup. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Single‐Cell Profiling of Bone Marrow B Cells and Early B Cell Developmental Disorders Associated With Systemic Lupus Erythematosus.
- Author
-
Dong, Chen, Guo, Yicheng, Chen, Zechuan, Li, Teng, Ji, Juan, Sun, Chi, Li, Jing, Cao, Haixia, Xia, Yunfei, Xue, Zhonghui, Gu, Xixi, Liang, Qian, Zhao, Rui, Fu, Ting, Ma, Jiaqiang, Jiang, Shan, Wu, Chunmei, Fu, Qiong, Guo, Genkai, and Bao, Yanfeng
- Subjects
- *
TYROSINE metabolism , *PHENYLALANINE metabolism , *FLOW cytometry , *IMMUNOGENETICS , *STATISTICAL correlation , *BLOOD testing , *GENOMICS , *CLUSTER analysis (Statistics) , *PHOSPHORYLATION , *QUALITATIVE research , *RESEARCH funding , *CELL physiology , *SYSTEMIC lupus erythematosus , *MANN Whitney U Test , *GLYCOPROTEINS , *QUANTITATIVE research , *RNA , *INTERFERONS , *GENE expression profiling , *METADATA , *ANALYSIS of variance , *METABOLISM , *COMPARATIVE studies , *COLLECTION & preservation of biological specimens , *CYTOKINES , *FACTOR analysis , *DATA analysis software , *GENETIC mutation , *B cells , *CELL separation , *SEQUENCE analysis , *GENETICS , *GENOTYPES , *DISEASE complications ,BONE marrow examination - Abstract
Objective: The peripheral B cell compartment is heavily disturbed in systemic lupus erythematosus (SLE), but whether B cells develop aberrantly in the bone marrow (BM) is largely unknown. Methods: We performed single‐cell RNA/B cell receptor (BCR) sequencing and immune profiling of BM B cells and classified patients with SLE into two groups: early B cell (Pro‐B and Pre‐B) normal (EBnor) and EB defective/low (EBlo) groups. Results: The SLE‐EBlo group exhibited more severe disease activity and proinflammatory status, overaction of type I interferon signaling and metabolic pathways within the B cell compartment, and aberrant BCR repertoires compared with the SLE‐EBnor group. Moreover, in one patient with SLE who was initially classified in the SLE‐EBlo group, early B cell deficiency and associated abnormalities were largely rectified in a second BM sample at the remission phase. Conclusion: In summary, this study suggests that early B cell loss in BM defines a unique pathological state in a subset of patients with SLE that may play an active role in the dysregulated autoimmune responses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Transforming Screening, Risk Stratification, and Treatment Optimization in Chronic Liver Disease Through Data Science and Translational Innovation.
- Author
-
Addissouky, Tamer A., Ali, Majeed M. A., El Sayed, Ibrahim El Tantawy, and Yuliang Wang
- Subjects
- *
LIVER diseases , *MEDICAL screening , *PROGNOSIS , *CHRONIC diseases , *DATA science - Abstract
Background: Chronic liver diseases like hepatocellular carcinoma (HCC) and primary biliary cholangitis (PBC) continue to face challenges in prognosis, treatment optimization, and understanding of mechanisms. Innovations in data integration and analytics could address these gaps. This review synthesizes innovative research improving prediction, understanding, detection, treatment, and translation in chronic liver disease. Method: Multiple studies leveraged approaches like machine learning and genomics. MAPS-CRAFITY integrates clinical variables, imaging, and AFP to predict immunotherapy/TKI response in HCC. Transformer modeling of RFA data improves outcome prediction to guide management. Genome-wide association analysis revealed IL21R as a PBC susceptibility gene in Chinese cohorts. Quantifying childhood MAFLD informs screening needs. Supporting the use of G6PD-deficient liver donors enables transplantation access expansion through risk stratification. Updating Baveno criteria enhances PBC prognosis. An HCC prognostic score identifies optimal RFA candidates. Conclusion: Recent research leverages diverse data types, genetics, imaging, and machine learning to develop integrated predictive systems that allow more personalized therapy selection. Elucidating molecular pathways provides therapeutic targets and prognostic biomarkers. Evidence-based screening and risk models facilitate delivering tailored interventions. Optimization of current modalities through prognostic validation and patient selection improves real-world effectiveness. Multifaceted modern research approaches promise to address unmet needs and transform hepatology care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
29. Characterisation of RAET1E/ULBP4 exon 4 and 3′ untranslated region genetic architecture reveals further diversity and allelic polymorphism.
- Author
-
Cox, Steven T., Haver, Daniel S., Patterson, Warren, Cambridge, Charlotte A., Turner, Thomas R., Danby, Robert D., and Hernandez, Diana
- Subjects
- *
KILLER cells , *TRANSMEMBRANE domains , *AMINO acid residues , *KILLER cell receptors , *IMMUNOGENETICS , *CORD blood - Abstract
NKG2D is a natural killer cell activating receptor recognising ligands on infected or tumorigenic cells, leading to their cytolysis. There are eight known genes encoding NKG2D ligands: MICA, MICB and ULBP1‐6. MICA and MICB are highly polymorphic and well characterised, whilst ULBP ligands are less polymorphic and the functional implication of their diversity is not well understood. Using International HLA and Immunogenetics Workshop (IHIW) cell line DNA, we previously characterised alleles of the RAET1E gene (encoding ULBP4 proteins), including the 5′ UTR promoter region and exons 1–3. We found 11 promoter haplotypes associating with alleles based on exons 1–3, revealing 19 alleles overall. The current study extends this analysis using 87 individual DNA samples from IHIW cell lines or cord blood to include RAET1E exon 4 and the 3′ UTR, as polymorphism in these regions have not been previously investigated. We found two novel exon 4 polymorphisms encoding amino acid substitutions altering the transmembrane domain. An amino acid substitution at residue 233 was unique to the RAET1E*008 allele whereas the substitution at residue 237 was shared between groups of alleles. Additionally, four haplotypes were found based on 3′ UTR sequences, which were unique to certain alleles or shared with allele groups based on exons 1–4 polymorphisms. Furthermore, putative microRNAs were identified that may interact with these polymorphic sites, repressing transcription and potentially affecting expression levels. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Predicting flow cytometry crossmatch results from single‐antigen bead testing.
- Author
-
Flynn, Patrick A., Fernando, Sebastian, Worthington, Judith E., and Poulton, Kay V.
- Subjects
- *
FLOW cytometry , *RECEIVER operating characteristic curves , *T cells , *B cells , *SERUM - Abstract
The aim of this study was to devise an algorithm that would predict flow cytometry crossmatch (FCXM) results using single‐antigen bead (SAB) mean fluorescent intensity (MFI) levels using samples received through the National External Quality Assurance Scheme (NEQAS) 2B external proficiency testing scheme between 2019 and 2023. A total of 159 serum samples were retrospectively screened using LABScreen Single Antigen Class I and II (SAB), and 40 peripheral blood samples were human leucocyte antigen (HLA) typed with LABType SSO. Donor‐specific antibodies were identified for each cell–serum combination tested, and cumulative MFI values were calculated for each test before correlating the screening result with the consensus crossmatch results for this scheme. HLA Class I MFIs were combined to predict the T cell crossmatch. For the B cell crossmatch prediction, two options were considered: (i) HLA Class II MFI values alone and (ii) HLA Class I + Class II MFIs. Receiver operating characteristic analysis was carried out to identify the combined MFI threshold that predicted NEQAS consensus results with the greatest sensitivity and specificity. HLA Class I combined MFI >5000 predicted T cell crossmatch results with 96% sensitivity, 100% specificity, 100% positive predictive value (PPV) and 92% negative predictive value (NPV). For B cell results, HLA Class I + Class II combined MFIs >11,000 gave the best model, showing 97% sensitivity, 82% specificity, 96% PPV and 85% NPV. However, for samples with only HLA Class II sensitization, combined MFIs >13,000 improved the B cell crossmatch predictions: 92% sensitivity, 95% specificity, 96% PPV and 91% NPV. Using this model, combined MFI can be used to predict the immunological risk posed by donor‐specific antibodies when it is not possible to carry out an FCXM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Saliva direct PCR protocol for HLA‐DQB1*02 genotyping.
- Author
-
Carrillo, Angeles, Manzur, María Jimena, and Juri Ayub, Maximiliano
- Subjects
- *
GLIADINS , *CELIAC disease , *MOLECULAR biology , *GLUTEN , *ALLELES , *INGESTION - Abstract
Celiac disease (CD) is an immune disorder, that is triggered by gluten ingestion in genetically predisposed individuals. The HLA‐DQB1*02 allele is the main predisposing genetic factor and a candidate for first‐line genotyping screening. We designed and validated a simple, DNA purification‐free PCR protocol directly from crude saliva, enabling the detection of the DQB1*02 allele. This assay also distinguishes homozygous from heterozygous carriers. We propose this method for use in mass screening and/or epidemiological studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. The immunogenetics of COVID-19
- Author
-
Srivastava, Anshika and Hollenbach, Jill A
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Pneumonia ,Biodefense ,Vaccine Related ,Prevention ,Clinical Research ,Immunization ,Pneumonia & Influenza ,Lung ,Emerging Infectious Diseases ,Infectious Diseases ,Aetiology ,2.1 Biological and endogenous factors ,Inflammatory and immune system ,Infection ,Good Health and Well Being ,Humans ,COVID-19 ,SARS-CoV-2 ,Immunogenetics ,Histocompatibility Antigens Class I ,Human leukocyte antigens ,Polymorphism ,Disease susceptibility - Abstract
The worldwide coronavirus disease 2019 pandemic was sparked by the severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2) that first surfaced in December 2019 (COVID-19). The effects of COVID-19 differ substantially not just between patients individually but also between populations with different ancestries. In humans, the human leukocyte antigen (HLA) system coordinates immune regulation. Since HLA molecules are a major component of antigen-presenting pathway, they play an important role in determining susceptibility to infectious disease. It is likely that differential susceptibility to SARS-CoV-2 infection and/or disease course in COVID-19 in different individuals could be influenced by the variations in the HLA genes which are associated with various immune responses to SARS-CoV-2. A growing number of studies have identified a connection between HLA variation and diverse COVID-19 outcomes. Here, we review research investigating the impact of HLA on individual responses to SARS-CoV-2 infection and/or progression, also discussing the significance of MHC-related immunological patterns and its use in vaccine design.
- Published
- 2023
33. Editorial: HLA in personalized medicine
- Author
-
Maneesh Kumar Misra, Ahmed Mostafa, and Dominique Charron
- Subjects
HLA ,immunogenetics ,TCR ,personalized medicine ,precision medicine ,Genetics ,QH426-470 - Published
- 2024
- Full Text
- View/download PDF
34. CCR5Δ32 and HLA allele diversity in bone marrow donors from southern Brazil
- Author
-
Bruna Kulmann-Leal, Joel Henrique Ellwanger, Ana Cristina Arend, Luiz Fernando Job Jobim, Mariana Jobim, Rafael Tomoya Michita, Sidia Maria Callegari-Jacques, Luís Cristóvão de Moraes Sobrino Pôrto, and José Artur Bogo Chies
- Subjects
CCR5Δ32 ,immunogenetics ,HIV ,HLA ,viral suppression ,Genetics ,QH426-470 - Abstract
Abstract Transplantation of stem cells derived from donors with CCR5Δ32 homozygous genotype is a potential strategy to achieve both the control of malignant hematological disease as well as sustained remission of the HIV infection, and researchers in different countries are looking for CCR5Δ32 homozygous donors to replicate such a ‘double-target’ strategy. We determined the frequency of the CCR5Δ32 variant in a sample of 1,398 bone marrow donors from Rio Grande do Sul State, Brazil. This study also evaluated whether HLA-A, HLA-B and HLA-DRB1 genotypes are homogeneously distributed between CCR5Δ32 carriers and non-carriers in a population characterized by a significant genetic admixture. The CCR5Δ32 allele frequency was 7.4% (CI0.95 6.4-8.4%), and the frequency of the Δ32/Δ32 homozygous genotype was 0.72% (CI0.95 0.34-1.31%). In general, HLA genotypes are homogeneously distributed between CCR5Δ32 carriers and non-carriers. Considering the large number of bone marrow donors in Brazil and the high CCR5Δ32 allele frequency observed in our study, our results clearly indicate the existence of a considerable amount of potential CCR5Δ32 homozygous bone marrow donors in southern Brazil, suggesting that an active search for these donors is not only feasible but an attractive and promising strategy towards effective HIV infection control and treatment.
- Published
- 2024
- Full Text
- View/download PDF
35. Editorial: HLA in personalized medicine.
- Author
-
Misra, Maneesh Kumar, Mostafa, Ahmed, and Charron, Dominique
- Published
- 2024
- Full Text
- View/download PDF
36. Techniques for Theoretical Prediction of Immunogenic Peptides
- Author
-
Robert Friedman
- Subjects
immunogenetics ,immunogenic peptides ,pathogenic organism ,vertebrate host ,computational models ,protein structure ,Science - Abstract
Small peptides are an important component of the vertebrate immune system. They are important molecules for distinguishing proteins that originate in the host from proteins derived from a pathogenic organism, such as a virus or bacterium. Consequently, these peptides are central for the vertebrate host response to intracellular and extracellular pathogens. Computational models for prediction of these peptides have been based on a narrow sample of data with an emphasis on the position and chemical properties of the amino acids. In past literature, this approach has resulted in higher predictability than models that rely on the geometrical arrangement of atoms. However, protein structure data from experiment and theory are a source for building models at scale, and, therefore, knowledge on the role of small peptides and their immunogenicity in the vertebrate immune system. The following sections introduce procedures that contribute to theoretical prediction of peptides and their role in immunogenicity. Lastly, deep learning is discussed as it applies to immunogenetics and the acceleration of knowledge by a capability for modeling the complexity of natural phenomena.
- Published
- 2024
- Full Text
- View/download PDF
37. Researchers Submit Patent Application, 'Cd94 Engineered Cell And Composition Thereof', for Approval (USPTO 20240226151)
- Subjects
Biochemistry ,Immunogenetics ,Stem cells ,Amino acids -- Intellectual property ,Health - Abstract
2024 JUL 29 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors LI, [...]
- Published
- 2024
38. External proficiency testing for histocompatibility and immunogenetics in today and future.
- Author
-
Oguz, Fatma Savran
- Subjects
HISTOCOMPATIBILITY testing ,IMMUNOGENETICS ,HLA histocompatibility antigens ,TRANSPLANTATION immunology ,QUALITY control ,STEM cell transplantation - Abstract
The Histocompatibility and Immunogenetics laboratories provide disease association and pharmacogenetic analyses as well as the tests required for transplantation immunology and transfusion medicine. They perform Human Leukocyte Antigen (HLA) genotyping in patients/recipients and potential donor candidates for solid organ and stem cell transplants using various molecular methods, and determine mismatches. In addition, they also perform HLA antibody tests to detect anti-HLA antibodies in patients and flow crossmatches to evaluate donor-recipient compatibility. Evidence-based clinical guidelines have emphasized the importance of laboratory tests in clinical practices for a long time. Understanding the principles of Quality Control and External Quality Assurance is a fundamental requirement for the effective management of Tissue Typing laboratories. When these processes are effectively implemented, errors in routine assays for transplantation are reduced and quality is improved. In this review, the importance of Quality Assurance, Quality control and proficiency testing in Histocompatibility and Immunogenetic testing, the necessity of external proficiency testing (EPT) for accreditation, and existing and potential EPT programmes will be reviewed and evaluated in the light of the literature. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Techniques for Theoretical Prediction of Immunogenic Peptides.
- Author
-
Friedman, Robert
- Subjects
- *
PEPTIDES , *CHEMICAL properties , *PROTEIN structure , *DEEP learning , *AMINO acids - Abstract
Definition: Small peptides are an important component of the vertebrate immune system. They are important molecules for distinguishing proteins that originate in the host from proteins derived from a pathogenic organism, such as a virus or bacterium. Consequently, these peptides are central for the vertebrate host response to intracellular and extracellular pathogens. Computational models for prediction of these peptides have been based on a narrow sample of data with an emphasis on the position and chemical properties of the amino acids. In past literature, this approach has resulted in higher predictability than models that rely on the geometrical arrangement of atoms. However, protein structure data from experiment and theory are a source for building models at scale, and, therefore, knowledge on the role of small peptides and their immunogenicity in the vertebrate immune system. The following sections introduce procedures that contribute to theoretical prediction of peptides and their role in immunogenicity. Lastly, deep learning is discussed as it applies to immunogenetics and the acceleration of knowledge by a capability for modeling the complexity of natural phenomena. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.
- Author
-
Carlson, Alise K., Amin, Moein, and Cohen, Jeffrey A.
- Subjects
- *
IMMUNOGENETICS , *PATIENT safety , *MULTIPLE sclerosis , *RITUXIMAB , *CENTRAL nervous system , *MONOCLONAL antibodies , *ANTIGENS , *DRUG approval , *DRUG efficacy , *DRUG tolerance , *B cells , *DISEASE progression , *IMMUNOMODULATORS - Abstract
Currently, there are four monoclonal antibodies (mAbs) that target the cluster of differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab, ocrelizumab, ofatumumab, and ublituximab. B-cell depletion therapy has changed the therapeutic landscape of MS through robust efficacy on clinical manifestations and MRI lesion activity, and the currently available anti-CD20 mAb therapies for use in MS are a cornerstone of highly effective disease-modifying treatment. Ocrelizumab is currently the only therapy with regulatory approval for primary progressive MS. There are currently few data regarding the relative efficacy of these therapies, though several clinical trials are ongoing. Safety concerns applicable to this class of therapeutics relate primarily to immunogenicity and mechanism of action, and include infusion-related or injection-related reactions, development of hypogammaglobulinemia (leading to increased infection and malignancy risk), and decreased vaccine response. Exploration of alternative dose/dosing schedules might be an effective strategy for mitigating these risks. Future development of biosimilar medications might make these therapies more readily available. Although anti-CD20 mAb therapies have led to significant improvements in disease outcomes, CNS-penetrant therapies are still needed to more effectively address the compartmentalized inflammation thought to play an important role in disability progression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Propositive follow‐up: Long‐term immune responses to the 4CMenB and MenACWY vaccines in people living with HIV.
- Author
-
San Francisco Ramos, Alberto, Isitt, Catherine, Athaide, Shehnaz, Ladhani, Shamez N., Andrews, Nicholas J., Townsend‐Payne, Kelly, Holland, Ann, Louth, Jennifer, Borrow, Ray, Heath, Paul T., and Cosgrove, Catherine A.
- Subjects
- *
HIV-positive persons , *CLINICAL trials , *IMMUNOGLOBULINS , *HUMAN research subjects , *SAMPLE size (Statistics) , *CONFIDENCE intervals , *TIME , *HEALTH outcome assessment , *MENINGOCOCCAL vaccines , *COMPARATIVE studies , *INFORMED consent (Medical law) , *DESCRIPTIVE statistics , *RESEARCH funding , *IMMUNOGENETICS , *NEISSERIA meningitidis , *DATA analysis software - Abstract
Background: People living with HIV have an increased risk of meningococcal disease. The Propositive trial evaluated co‐administration of two doses of a four‐component recombinant protein‐based MenB vaccine (4CMenB) and a quadrivalent conjugate polysaccharide MenACWY vaccine (MenACWY‐CRM197) given 1 month apart in people with HIV. The follow‐up trial assessed the immunogenicity of these vaccines at 1.5 and 2.5 years after primary vaccination. Methods: Participants who completed the parent Propositive trial were invited to the follow‐up study. Immunogenicity analysis was performed at 18 and 30 months after primary vaccination. Primary outcome measures were serum bactericidal antibody (SBA) geometric mean titres (GMTs) against three MenB reference strains and the proportion of participants maintaining a protective SBA titre of ≥4 at 18 and 30 months. Secondary outcome measures were SBA GMTs against MenA, C, W, and Y serogroups and the proportion of participants maintaining a protective SBA titre of ≥8 at 18 and 30 months. The trial is registered with Clinicaltrials.gov (NCT042394300). Results: A total of 40 participants aged 22–47 years were enrolled. Geometric mean titres waned by 18 and 30 months but remained higher than pre‐vaccination for all MenB strains and MenA, C, W, and Y. In total, 75%–85% of participants retained protective SBA titres by 30 months against individual MenB strains, whereas 68.8% of patients retained protective antibody titres against all three MenB strains. Antibodies against MenC waned more rapidly than did those against MenA, W, and Y. The proportion of participants with protective titres against MenC at 30 months was also lower (46.9%) than that with protective titres against MenA (87.5%), W (78.1%), and Y (87.5%). Conclusions: Immune responses against MenB in our cohort of people living with HIV at 2.5 years of follow‐up were reassuring, with 68.8% of participants retaining protection against all three reference strains. However, responses against MenC were lower than those against MenA, W, and Y serogroups. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Immunoglobulin G genetic variation can confound assessment of antibody levels via altered binding to detection reagents.
- Author
-
Purcell, Ruth A, Aurelia, L Carissa, Esterbauer, Robyn, Allen, Lilith F, Bond, Katherine A, Williamson, Deborah A, Trevillyan, Janine M, Trubiano, Jason A, Juno, Jennifer J, Wheatley, Adam K, Davenport, Miles P, Nguyen, Thi HO, Kedzierska, Katherine, Kent, Stephen J, Selva, Kevin John, and Chung, Amy W
- Subjects
- *
GENETIC variation , *IMMUNOGLOBULIN G , *IMMUNOGENETICS , *HUMORAL immunity , *ANTIBODY formation , *IMMUNOGLOBULINS - Abstract
Objectives: Amino acid variations across more than 30 immunoglobulin (Ig) allotypes may introduce structural changes that influence recognition by anti‐Ig detection reagents, consequently confounding interpretation of antibody responses, particularly in genetically diverse cohorts. Here, we assessed a panel of commercial monoclonal anti‐IgG1 clones for capacity to universally recognise two dominant IgG1 haplotypes (G1m‐1,3 and G1m1,17). Methods: Four commercial monoclonal anti‐human IgG1 clones were assessed via ELISAs and multiplex bead‐based assays for their ability to bind G1m‐1,3 and G1m1,17 IgG1 variants. Detection antibodies were validated against monoclonal IgG1 allotype standards and tested for capacity to recognise antigen‐specific plasma IgG1 from G1m‐1,3 and G1m1,17 homozygous and heterozygous SARS‐CoV‐2 BNT162b2 vaccinated (n = 28) and COVID‐19 convalescent (n = 44) individuals. An Fc‐specific pan‐IgG detection antibody corroborated differences between hinge‐ and Fc‐specific anti‐IgG1 responses. Results: Hinge‐specific anti‐IgG1 clone 4E3 preferentially bound G1m1,17 compared to G1m‐1,3 IgG1. Consequently, SARS‐CoV‐2 Spike‐specific IgG1 levels detected in G1m1,17/G1m1,17 BNT162b2 vaccinees appeared 9‐ to 17‐fold higher than in G1m‐1,3/G1m‐1,3 vaccinees. Fc‐specific IgG1 and pan‐IgG detection antibodies equivalently bound G1m‐1,3 and G1m1,17 IgG1 variants, and detected comparable Spike‐specific IgG1 levels between haplotypes. IgG1 responses against other human coronaviruses and influenza were similarly poorly detected by 4E3 anti‐IgG1 in G1m‐1,3/G1m‐1,3 subjects. Conclusion: Anti‐IgG1 clone 4E3 confounds assessment of antibody responses in clinical cohorts owing to bias towards detection of G1m1,17 IgG1 variants. Validation of anti‐Ig clones should include evaluation of binding to relevant antibody variants, particularly as the role of immunogenetics upon humoral immunity is increasingly explored in diverse populations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. GenIA, the Genetic Immunology Advisor database for inborn errors of immunity.
- Author
-
Caballero-Oteyza, Andrés, Crisponi, Laura, Peng, Xiao P., Yauy, Kevin, Volpi, Stefano, Giardino, Stefano, Freeman, Alexandra F., Grimbacher, Bodo, and Proietti, Michele
- Abstract
To date, no publicly accessible platform has captured and synthesized all of the layered dimensions of genotypic, phenotypic, and mechanistic information published in the field of inborn errors of immunity (IEIs). Such a platform would represent the extensive and complex landscape of IEIs and could increase the rate of diagnosis in patients with a suspected IEI, which remains unacceptably low. Our aim was to create an expertly curated, patient-centered, multidimensional IEI database that enables aggregation and sophisticated data interrogation and promotes involvement from diverse stakeholders across the community. The database structure was designed following a subject-centered model and written in Structured Query Language (SQL). The web application is written in Hypertext Preprocessor (PHP), Hypertext Markup Language (HTML), Cascading Style Sheets (CSS), and JavaScript. All data stored in the Genetic Immunology Advisor (GenIA) are extracted by manually reviewing published research articles. We completed data collection and curation for 24 pilot genes. Using these data, we have exemplified how GenIA can provide quick access to structured, longitudinal, more thorough, comprehensive, and up-to-date IEI knowledge than do currently existing databases, such as ClinGen, Human Phenotype Ontology (HPO), ClinVar, or Online Mendelian Inheritance in Man (OMIM), with which GenIA intends to dovetail. GenIA strives to accurately capture the extensive genetic, mechanistic, and phenotypic heterogeneity found across IEIs, as well as genetic paradigms and diagnostic pitfalls associated with individual genes and conditions. The IEI community's involvement will help promote GenIA as an enduring resource that supports and improves knowledge sharing, research, diagnosis, and care for patients with genetic immune disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. The genome and transcriptome of the snail Biomphalaria sudanica s.l.: immune gene diversification and highly polymorphic genomic regions in an important African vector of Schistosoma mansoni.
- Author
-
Pennance, Tom, Calvelo, Javier, Tennessen, Jacob A., Burd, Ryan, Cayton, Jared, Bollmann, Stephanie R., Blouin, Michael S., Spaan, Johannie M., Hoffmann, Federico G., Ogara, George, Rawago, Fredrick, Andiego, Kennedy, Mulonga, Boaz, Odhiambo, Meredith, Loker, Eric S., Laidemitt, Martina R., Lu, Lijun, Iriarte, Andrés, Odiere, Maurice R., and Steinauer, Michelle L.
- Abstract
Background: Control and elimination of schistosomiasis is an arduous task, with current strategies proving inadequate to break transmission. Exploration of genetic approaches to interrupt Schistosoma mansoni transmission, the causative agent for human intestinal schistosomiasis in sub-Saharan Africa and South America, has led to genomic research of the snail vector hosts of the genus Biomphalaria. Few complete genomic resources exist, with African Biomphalaria species being particularly underrepresented despite this being where the majority of S. mansoni infections occur. Here we generate and annotate the first genome assembly of Biomphalaria sudanica sensu lato, a species responsible for S. mansoni transmission in lake and marsh habitats of the African Rift Valley. Supported by whole-genome diversity data among five inbred lines, we describe orthologs of immune-relevant gene regions in the South American vector B. glabrata and present a bioinformatic pipeline to identify candidate novel pathogen recognition receptors (PRRs). Results: De novo genome and transcriptome assembly of inbred B. sudanica originating from the shoreline of Lake Victoria (Kisumu, Kenya) resulted in a haploid genome size of ~ 944.2 Mb (6,728 fragments, N50 = 1.067 Mb), comprising 23,598 genes (BUSCO = 93.6% complete). The B. sudanica genome contains orthologues to all described immune genes/regions tied to protection against S. mansoni in B. glabrata, including the polymorphic transmembrane clusters (PTC1 and PTC2), RADres, and other loci. The B. sudanica PTC2 candidate immune genomic region contained many PRR-like genes across a much wider genomic region than has been shown in B. glabrata, as well as a large inversion between species. High levels of intra-species nucleotide diversity were seen in PTC2, as well as in regions linked to PTC1 and RADres orthologues. Immune related and putative PRR gene families were significantly over-represented in the sub-set of B. sudanica genes determined as hyperdiverse, including high extracellular diversity in transmembrane genes, which could be under pathogen-mediated balancing selection. However, no overall expansion in immunity related genes was seen in African compared to South American lineages. Conclusions: The B. sudanica genome and analyses presented here will facilitate future research in vector immune defense mechanisms against pathogens. This genomic/transcriptomic resource provides necessary data for the future development of molecular snail vector control/surveillance tools, facilitating schistosome transmission interruption mechanisms in Africa. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Advancing precision in histocompatibility and immunogenetics: a comprehensive review of the UCLA exchange program.
- Author
-
Qiuheng Zhang, Locke, Arlene F., Carolina Alvarez, Andrea, Cabarong, Maria L., Lek Ching Liv, Alfaro, Belen Garcia P., Gjertson, David W., and Reed, Elaine F.
- Subjects
EXCHANGE of persons programs ,IMMUNOGENETICS ,HLA histocompatibility antigens ,HISTOCOMPATIBILITY ,HEMATOPOIETIC stem cells ,ALLELES - Abstract
Precise typing of human leukocyte antigens (HLA) is crucial for clinical hematopoietic stem cell and solid organ transplantations, transfusion medicine, HLA-related disease association, and drug hypersensitivity analysis. The UCLA Cell Exchange program has played a vital role in providing educational and proficiency testing surveys to HLA laboratories worldwide for the past 5 decades. This article highlights the significant contribution of the UCLA Cell and DNA Exchange Programs in advancing HLA antibody testing, genotyping, crossmatches, and, more recently, virtual crossmatches. Additionally, we discuss future directions of the UCLA Cell Exchange program to support histocompatibility testing to adapt to the fast-evolving field of immunotherapy, tolerance and xenotransplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Evaluation of 19years of international external proficiency testing for high-resolution HLA typing.
- Author
-
Voorter, C. E. M., Groeneveld, L., Heidt, S., and Wieten, L.
- Subjects
EUROPEAN integration ,IMMUNOGENETICS ,TESTING laboratories ,ALLELES ,LEUCOCYTES ,TANDEM repeats - Abstract
The international high-resolution external proficiency testing (EPT) started in 2004 with high-resolution typing of human leucocyte antigen (HLA) class I (HLA-A,B,C) and HLA class II (HLA-DRB1, DRB345, DQB1, and DPB1) alleles, since possibilities for such an EPT within Europe were limited and all existing EPTs at that time made use of the comparison of HLA typing results without a reference. This EPT was set up as a collaboration between the HLA laboratory of Leiden, providing DNA samples to the participants, and the laboratory of Maastricht, performing the high-resolution typing as the reference result and evaluating the results of all participants according to the prevailing European Federation for Immunogenetics (EFI) standards. Once a year, 12 samples were sent to the participating laboratories, and evaluation and certificates were provided at the end of that same year. During the years, the EPT was extended to lowresolution HLA class I and II typing, high-resolution typing including DQA1 and DPA1, and allelic resolution typing for HLA class I, the latter one being unique in this field. Evaluation of the high-resolution typing results of the last 19 years showed a clear increase in the number of loci tested by the participating laboratories and a clear change of method from Sanger sequencing with additional other techniques (SSO/SSP) to the nowadays widely used nextgeneration sequencing method. By strictly using the EFI rules for highresolution HLA typing, the participants were made aware of the ambiguities within exons 2 and 3 for class I and exon 2 for class II and the presence of null alleles even in a two-field HLA typing. There was an impressive learning curve, resulting in >98% correctly typed samples since 2017 and a 100% fulfillment of EFI rules for all laboratories for all loci submitted in the last 2 years. Overall, this EPT meets the need of an EPT for high-resolution typing for EFI accreditation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Immunogenetic Aspects of Sarcopenic Obesity.
- Author
-
Mazurkiewicz, Łukasz, Czernikiewicz, Krystian, and Grygiel-Górniak, Bogna
- Subjects
- *
BODY composition , *OBESITY , *ADIPOSE tissues , *SARCOPENIA , *MUSCLE mass , *GENETIC variation , *IMMUNOGENETICS - Abstract
Sarcopenic obesity (SO) is a combination of obesity and sarcopenia, with diagnostic criteria defined as impaired skeletal muscle function and altered body composition (e.g., increased fat mass and reduced muscle mass). The mechanism of SO is not yet perfectly understood; however, the pathogenesis includes aging and its complications, chronic inflammation, insulin resistance (IR), and hormonal changes. Genetic background is apparent in the pathogenesis of isolated obesity, which is most often polygenic and is characterized by the additive effect of various genetic factors. The genetic etiology has not been strictly established in SO. Still, many data confirm the existence of pathogenic gene variants, e.g., Fat Mass and Obesity Associated Gene (FTO), beta-2-adrenergic receptor (ADRB2) gene, melanocortin-4 receptor (MC4R) and others with obesity. The literature on the role of these genes is scarce, and their role has not yet been thoroughly established. On the other hand, the involvement of systemic inflammation due to increased adipose tissue in SO plays a significant role in its pathophysiology through the synthesis of various cytokines such as monocyte chemoattractant protein-1 (MCP-1), IL-1Ra, IL-15, adiponectin or CRP. The lack of anti-inflammatory cytokine (e.g., IL-15) can increase SO risk, but further studies are needed to evaluate the exact mechanisms of implications of various cytokines in SO individuals. This manuscript analyses various immunogenetic and non-genetic factors and summarizes the recent findings on immunogenetics potentially impacting SO development. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Leukocyte immunoglobulin‐like receptor A3 gene deletion in five Chinese populations and protective association with nasopharyngeal carcinoma.
- Author
-
Tian, Wei, Li, Li Xin, Cheng, Wen, Jin, He Kun, and Zhang, Sha Shuang
- Subjects
- *
CHINESE people , *NASOPHARYNX cancer , *DELETION mutation , *KILLER cell receptors , *TRANSMEMBRANE domains , *LEUCOCYTES - Abstract
Among the thirteen leukocyte Ig‐like receptor (LILR) loci located at 19q13.4, LILRA3 is unique in that it encodes a soluble protein lacking the transmembrane and cytoplasmic domains, and a 6.7 kb deletion spanning the first seven exons has been detected in some human individuals. Presently, there is a lack of data about the distribution of LILRA3 gene deletion in more diverse ethnic groups. Also, no previous studies have investigated the correlation between copy number variation (CNV) of LILRA3 and nasopharyngeal carcinoma (NPC). In this study, five populations from China mainland: two Southern Han populations, Hunan (N = 1478) and Guandong (N = 107); one Southeastern Han population, Fujian (N = 439); and two Northern populations, Inner Mongolia Han (N = 104) and Mongol population from Inner Mongolia (N = 158) were investigated for CNV of LILRA3 using polymerase chain reaction‐sequence‐specific priming (PCR‐SSP) method. LILRA3 variants were also examined in a cohort of NPC cases (N = 1142) in Hunan Han population. The five Chinese populations demonstrated northward increase in frequency of the deleted form of LILRA3 gene (LILRA3*Del) (all corrected p values < 0.05). Inter‐population comparison also uncovered significant differentiation in the distribution of CNV of LILRA3 among modern human populations. LILRA3*Del was found to confer significantly reduced risk to NPC in Hunan Han population (at allelic level: OR = 0.79, 95% CI = 0.71–0.89, p < 0.0001; at genotype level: OR = 0.63, 95% CI = 0.51–0.79, p < 0.0001). No interaction was found between LILRA3 variants and HLA‐A*02:07, HLA‐A*11:01, HLA‐B*13 and HLA‐B*46:01 alleles in susceptibility to NPC. Our study constitutes the first demonstration of LILRA3 gene as a locus linked to NPC susceptibility in a southern Chinese population. Future independent studies in other populations are warranted to confirm the findings reported in this study. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. CCR5 promoter region polymorphisms in systemic lupus erythematosus.
- Author
-
Schauren, Juliana da Silveira, de Oliveira, Amanda Henrique, Consiglio, Camila Rosat, Monticielo, Odirlei André, Xavier, Ricardo Machado, Nunes, Natália Schneider, Ellwanger, Joel Henrique, and Chies, José Artur Bogo
- Subjects
- *
SYSTEMIC lupus erythematosus , *CHEMOKINE receptors , *PROMOTERS (Genetics) , *HAPLOTYPES , *SINGLE nucleotide polymorphisms , *DISEASE susceptibility - Abstract
This study investigated the impacts of CCR5 promoter region polymorphisms on the development of systemic lupus erythematosus (SLE) by comparing CCR5 genotypes and haplotypes from SLE patients with ethnically matched controls. A total of 382 SLE patients (289 European‐derived and 93 African‐derived) and 375 controls (243 European‐derived and 132 African‐derived) were genotyped for the CCR2‐64I G > A (rs1799864), CCR5‐59353 C > T (rs1799988), CCR5‐59356 C > T (rs41469351), CCR5‐59402 A > G (rs1800023) and CCR5‐59653 C > T (rs1800024) polymorphisms through polymerase chain reaction‐restriction fragment length polymorphism and direct sequencing. Previous data from CCR5Δ32 analysis was included in the study to infer the CCR5 haplotypes and as a possible confounding factor in the binary logistic regression. European‐derived patients showed a higher frequency of CCR5 wild‐type genotype (conversely, a reduced frequency of Δ32 allele) and a reduced frequency of the HHG*2 haplotype compared to controls; both factors significantly affecting disease risk [p =.003 (OR 3.5, 95%CI 1.6–7.5) and 2.0% vs. 7.2% (residual p = 2.9E − 5), respectively]. Additionally, the HHA/HHB, HHC and HHG*2 haplotype frequencies differed between African‐derived patients and controls [10% vs. 20.5% (residual p =.003), 29.4% vs. 17.4% (residual p =.003) and 3.9% vs. 0.8% (residual p =.023), respectively]. Considering the clinical manifestations of the disease, the CCR5Δ32 presence was confirmed as a susceptibility factor to class IV nephritis in the African‐derived group and when all patients were grouped for comparison [pcorrected =.012 (OR 3.0; 95%CI 3.0–333.3) and pcorrected =.0006 (OR 6.8; 95%CI 1.9–24.8), respectively]. In conclusion, this study indicates that CCR5 promoter polymorphisms are important disease modifiers in SLE. Present data reinforces the CCR5Δ32 polymorphism as a protective factor for the development of the disease in European‐derived patients and as a susceptibility factor for class IV nephritis in African‐derived patients. Furthermore, we also described a reduced frequency of HHA/HHB and an increased frequency of HHC and HHG*2 haplotypes in African‐derived patients, which could modify the CCR5 protein expression in specific cell subsets. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of-heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers.
- Author
-
Wan Ching Lim, Marques Da Costa, Maria Eugenia, Godefroy, Karine, Jacquet, Eric, Gragert, Loren, Rondof, Windy, Marchais, Antonin, Nhiri, Naima, Dalfovo, Davide, Viard, Mathias, Labaied, Nizar, Khan, Asif M., Dessen, Philippe, Romanel, Alessandro, Pasqualini, Claudia, Schleiermacher, Gudrun, Carrington, Mary, Zitvogel, Laurence, Scoazec, Jean-Yves, and Geoerger, Birgit
- Subjects
NEUROBLASTOMA ,CHILDHOOD cancer ,TUMOR-infiltrating immune cells ,HLA histocompatibility antigens ,SOMATIC mutation ,EWING'S sarcoma - Abstract
The human leukocyte antigen (HLA) system is a major factor controlling cancer immunosurveillance and response to immunotherapy, yet its status in pediatric cancers remains fragmentary. We determined high-confidence HLA genotypes in 576 children, adolescents and young adults with recurrent/refractory solid tumors from the MOSCATO-01 and MAPPYACTS trials, using normal and tumor whole exome and RNA sequencing data and benchmarked algorithms. There was no evidence for narrowed HLA allelic diversity but discordant homozygosity and allele frequencies across tumor types and subtypes, such as in embryonal and alveolar rhabdomyosarcoma, neuroblastoma MYCN and 11q subtypes, and high-grade glioma, and several alleles may represent protective or susceptibility factors to specific pediatric solid cancers. There was a paucity of somatic mutations in HLA and antigen processing and presentation (APP) genes in most tumors, except in cases with mismatch repair deficiency or genetic instability. The prevalence of loss-of-heterozygosity (LOH) ranged from 5.9 to 7.7% in HLA class I and 8.0 to 16.7% in HLA class II genes, but was widely increased in osteosarcoma and glioblastoma (~15-25%), and for DRB1-DQA1-DQB1 in Ewing sarcoma (~23-28%) and low-grade glioma (~33-50%). HLA class I and HLA-DR antigen expression was assessed in 194 tumors and 44 patient-derived xenografts (PDXs) by immunochemistry, and class I and APP transcript levels quantified in PDXs by RT-qPCR. We confirmed that HLA class I antigen expression is heterogeneous in advanced pediatric solid tumors, with class I loss commonly associated with the transcriptional downregulation of HLA-B and transporter associated with antigen processing (TAP) genes, whereas class II antigen expression is scarce on tumor cells and occurs on immune infiltrating cells. Patients with tumors expressing sufficient HLA class I and TAP levels such as some glioma, osteosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft-tissue sarcoma cases may more likely benefit from T cell-based approaches, whereas strategies to upregulate HLA expression, to expand the immunopeptidome, and to target TAP-independent epitopes or possibly LOH might provide novel therapeutic opportunities in others. The consequences of HLA class II expression by immune cells remain to be established. Immunogenetic profiling should be implemented in routine to inform immunotherapy trials for precision medicine of pediatric cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.